BR112015030918A2 - método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais - Google Patents

método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais

Info

Publication number
BR112015030918A2
BR112015030918A2 BR112015030918A BR112015030918A BR112015030918A2 BR 112015030918 A2 BR112015030918 A2 BR 112015030918A2 BR 112015030918 A BR112015030918 A BR 112015030918A BR 112015030918 A BR112015030918 A BR 112015030918A BR 112015030918 A2 BR112015030918 A2 BR 112015030918A2
Authority
BR
Brazil
Prior art keywords
progenitor cells
renal progenitor
cells
producing
drugs containing
Prior art date
Application number
BR112015030918A
Other languages
English (en)
Inventor
Osafune Kenji
Toyohara Takafumi
Yamagishi Yukiko
Original Assignee
Astellas Pharma Inc
Univ Kyoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Univ Kyoto filed Critical Astellas Pharma Inc
Publication of BR112015030918A2 publication Critical patent/BR112015030918A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0687—Renal stem cells; Renal progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Abstract

a presente invenção fornece: um método para produção de células progenitoras renais a partir de células mesodérmicas intermediárias, o método incluindo uma etapa para cultivo de células meso-dérmicas intermediárias em um meio de cultura que contém um ativador de sinalização de tgfss e um inibidor de bmp; as células progenitoras renais produzidas pelo método; uma composição farmacêutica contendo as células; e um agente terapêutico para doenças renais que compreendem as células.
BR112015030918A 2013-06-11 2014-06-11 método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais BR112015030918A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013123072 2013-06-11
JP2014092108 2014-04-25
PCT/JP2014/066081 WO2014200115A1 (ja) 2013-06-11 2014-06-11 腎前駆細胞の製造方法及び腎前駆細胞を含む医薬

Publications (1)

Publication Number Publication Date
BR112015030918A2 true BR112015030918A2 (pt) 2017-12-05

Family

ID=52022399

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015030918A BR112015030918A2 (pt) 2013-06-11 2014-06-11 método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais

Country Status (15)

Country Link
US (1) US11225642B2 (pt)
EP (1) EP3020803B1 (pt)
JP (1) JP6450311B2 (pt)
KR (1) KR102145967B1 (pt)
CN (1) CN105283542A (pt)
AU (1) AU2014279065B2 (pt)
BR (1) BR112015030918A2 (pt)
CA (1) CA2915085C (pt)
ES (1) ES2794074T3 (pt)
IL (1) IL243023B (pt)
MX (1) MX2015017036A (pt)
RU (1) RU2696315C2 (pt)
SG (1) SG11201510201PA (pt)
TW (1) TWI629360B (pt)
WO (1) WO2014200115A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794860B1 (en) * 2011-12-19 2017-05-03 Kyoto University Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells
NZ715302A (en) * 2013-06-14 2021-12-24 Univ Queensland Renal progenitor cells
EP3027737B1 (en) * 2013-07-29 2018-12-26 F.Hoffmann-La Roche Ag Method for differentiation of pluripotent stem cells into multi-competent renal precursors
KR101853477B1 (ko) * 2015-06-24 2018-04-30 전북대학교산학협력단 Sirt1 발현 조절을 통한 배아줄기세포로부터 신장전구세포로의 분화 조절 방법
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2016321015B2 (en) 2015-09-11 2021-09-30 Astellas Pharma Inc. Method for producing renal progenitor cells
WO2017049243A1 (en) * 2015-09-17 2017-03-23 Bonventre Joseph V Methods of generating nephrons from human pluripotent stem cells
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
JP7201223B2 (ja) * 2016-04-08 2023-01-10 国立大学法人京都大学 多能性幹細胞から、内胚葉系細胞を選択的に誘導する方法
JP2019537729A (ja) 2016-09-28 2019-12-26 オルガノボ インコーポレイテッド アッセイにおける人工腎臓組織の使用
EP3527655A4 (en) 2016-10-11 2020-05-06 Tokushima University METHOD FOR PRODUCING RENAL-LIKE BIOLOGICAL TISSUE
JP7274683B2 (ja) * 2017-04-25 2023-05-17 国立大学法人 熊本大学 多能性幹細胞から樹状分岐した集合管を伴う腎臓構造を作製する方法
BR112019024637A2 (pt) 2017-05-25 2020-06-16 Kyoto University Método para produzir células progenitoras renais, célula progenitora renal, organoide renal, composição farmacêutica, e, agente terapêutico para uma doença renal.
JP2021500929A (ja) * 2017-10-31 2021-01-14 マードック チルドレンズ リサーチ インスティテュート 組成物および方法
US11859209B2 (en) 2017-12-19 2024-01-02 Kyoto University Method for inducing osteogenic differentiation
EP3828262A4 (en) * 2018-07-23 2022-03-30 Kyoto University NOVEL RENAL PROGENITOR CELL MARKER AND METHOD OF RENAL PROGENITOR CELL CONCENTRATION USING THE SAME
WO2022149616A1 (ja) 2021-01-08 2022-07-14 国立大学法人京都大学 ネフロン前駆細胞を拡大培養するための培地、ネフロン前駆細胞を拡大培養する方法、腎臓オルガノイドの製造方法
WO2023017848A1 (ja) 2021-08-11 2023-02-16 国立大学法人京都大学 腎間質前駆細胞の製造方法並びにエリスロポエチン産生細胞、およびレニン産生細胞の製造方法
CN114457006B (zh) * 2022-02-21 2023-07-28 广州华越肾科再生医学科技有限公司 一种通过不连续分化制备肾脏足细胞的方法
CN114702591B (zh) * 2022-05-17 2022-09-23 诺赛联合(北京)生物医学科技有限公司 成体细胞衍生的类器官制备技术
CN117305222B (zh) * 2023-11-28 2024-02-20 广州华越肾科再生医学科技有限公司 多能干细胞分化为肾祖细胞的方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
HN2002000067A (es) 2001-03-23 2003-10-24 Bayer Healthcare Llc Inhibidores de la rho - quinasa.
MXPA03008659A (es) 2001-03-23 2005-04-08 Bayer Ag Inhibidores de rho-cinasa.
WO2003059913A1 (en) 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
US9453219B2 (en) 2003-05-15 2016-09-27 Mello Biotech Taiwan Co., Ltd. Cosmetic designs and products using intronic RNA
AU2003902776A0 (en) 2003-06-03 2003-06-19 Monash University Method for expanding cells
US20070031966A1 (en) * 2005-07-18 2007-02-08 Regents Of The University Of Michigan Renal progenitor cells from embryonic stem cells
ES2367525T3 (es) 2005-12-13 2011-11-04 Kyoto University Factor de reprogramación celular.
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP2126045A4 (en) * 2007-01-30 2010-05-26 Univ Georgia EARLY MESODERM CELLS, STABLE POPULATION OF MESENDODERM CELLS WITH THE ABILITY TO GENERATE ENDODERM AND MESODERM CELL LINES AND MULTIPOTENTIAL MIGRATION CELLS
KR101516833B1 (ko) 2007-03-23 2015-05-07 위스콘신 얼럼나이 리서어치 화운데이션 체세포 재프로그래밍
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
CA3006367A1 (en) 2007-08-31 2009-03-12 Whitehead Institute For Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
CA2660123C (en) 2007-10-31 2017-05-09 Kyoto University Nuclear reprogramming method
AU2008286249B2 (en) 2007-12-10 2013-10-10 Kyoto University Efficient method for nuclear reprogramming
US20100330063A1 (en) 2007-12-17 2010-12-30 Gliamed, Inc. Stem-like cells, method for de-differentiating mammalian somatic cells into stem-like cells, and method for differentiating stem-like cells
CN101970664B (zh) 2008-01-16 2013-08-21 林希龙 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞
US20100330677A1 (en) 2008-02-11 2010-12-30 Cambridge Enterprise Limited Improved Reprogramming of Mammalian Cells, and Cells Obtained
EP2090649A1 (en) 2008-02-13 2009-08-19 Fondazione Telethon Method for reprogramming differentiated cells
US20110014164A1 (en) 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP2955222B1 (en) 2008-03-17 2018-09-12 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
WO2009114949A1 (en) 2008-03-20 2009-09-24 UNIVERSITé LAVAL Methods for deprogramming somatic cells and uses thereof
KR20110007607A (ko) 2008-04-07 2011-01-24 뉴포텐셜, 인크. 소분자 조절제의 사용을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
EP2288692B1 (en) 2008-06-27 2017-08-02 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US9453204B2 (en) 2008-07-14 2016-09-27 Oklahoma Medical Research Foundation Production of pluripotent cells through inhibition of bright/ARID3a function
WO2010147612A1 (en) 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010033920A2 (en) 2008-09-19 2010-03-25 Whitehead Institute For Biomedical Research Compositions and methods for enhancing cell reprogramming
WO2010042800A1 (en) 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
EP2342333A4 (en) 2008-10-30 2013-05-08 Univ Kyoto METHOD FOR THE PRODUCTION OF INDUCED PLURIPOTENTAL STEM CELLS
US20100111908A1 (en) * 2008-11-03 2010-05-06 Fangming Lin Induction of Renal Cells for Treatment of Kidney Disease
WO2010056831A2 (en) 2008-11-12 2010-05-20 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an hdac modulator
EP2376626A4 (en) 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)
WO2010097794A1 (en) * 2009-02-26 2010-09-02 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of reprogramming renal cells
US8951801B2 (en) 2009-02-27 2015-02-10 Kyoto University Method for making IPS cells
WO2010102267A2 (en) 2009-03-06 2010-09-10 Ipierian, Inc. Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
WO2010111409A2 (en) 2009-03-25 2010-09-30 The Salk Institute For Biological Studies Pluripotent stem cells
WO2010111422A2 (en) 2009-03-25 2010-09-30 The Salk Institute For Biological Studies Induced pluripotent stem cell generation using two factors and p53 inactivation
US8852940B2 (en) 2009-04-01 2014-10-07 The Regents Of The University Of California Embryonic stem cell specific microRNAs promote induced pluripotency
US20110088107A1 (en) 2009-04-24 2011-04-14 Yaqub Hanna Compositions and methods for deriving or culturing pluripotent cells
WO2010147395A2 (en) 2009-06-16 2010-12-23 Korea Research Institute Of Bioscience And Biotechnology Medium composition comprising neuropeptide y for the generation, maintenance, prologned undifferentiated growth of pluripotent stem cells and method of culturing pluripotent stem cell using the same
US9121011B2 (en) 2010-07-21 2015-09-01 Kyoto University Method for inducing differentiation of human pluripotent stem cell into intermediate mesoderm cell
EP2794860B1 (en) * 2011-12-19 2017-05-03 Kyoto University Method for inducing differentiation of human pluripotent stem cells into intermediate mesoderm cells

Also Published As

Publication number Publication date
CN105283542A (zh) 2016-01-27
KR20160019509A (ko) 2016-02-19
RU2015156492A (ru) 2017-07-14
TW201536917A (zh) 2015-10-01
US11225642B2 (en) 2022-01-18
CA2915085C (en) 2021-04-27
AU2014279065B2 (en) 2020-04-09
IL243023B (en) 2019-05-30
JPWO2014200115A1 (ja) 2017-02-23
RU2015156492A3 (pt) 2018-04-02
RU2696315C2 (ru) 2019-08-01
TWI629360B (zh) 2018-07-11
CA2915085A1 (en) 2014-12-18
MX2015017036A (es) 2016-07-21
KR102145967B1 (ko) 2020-08-19
EP3020803A1 (en) 2016-05-18
JP6450311B2 (ja) 2019-01-09
EP3020803A4 (en) 2017-02-22
AU2014279065A1 (en) 2016-01-21
US20160137985A1 (en) 2016-05-19
WO2014200115A1 (ja) 2014-12-18
SG11201510201PA (en) 2016-01-28
EP3020803B1 (en) 2020-03-11
ES2794074T3 (es) 2020-11-17

Similar Documents

Publication Publication Date Title
BR112015030918A2 (pt) método para produção de células progenitoras renais, e fármacos contendo células progenitoras renais
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
CL2015000529A1 (es) Inhibidores de glucosilceramida sintasa.
TN2015000050A1 (en) Methods of treating a tauopathy
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
UA115773C2 (uk) Пірольні сполуки, спосіб їх одержання та фармацевтична композиція, що їх містить (варіанти)
CL2013003123A1 (es) Molécula de nucleasa híbrida; composición que comprende dicha molécula; método para preparar dicha molécula; método para tratar lupus eritematoso sistémico.
BR112013018352A2 (pt) composição de minociclina tópica e método
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
MX2015016240A (es) Metodos para tratar una tauopatia.
CR20170236A (es) Método para producir sistema de administración farmacéutica, uso de carbonato de calcio y sistema de administración farmacéutica obtenido por método
BR112013004440A2 (pt) método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral
BR112013025853A2 (pt) documento de segurança (1-1), método para fabricar um ou mais elementos personalizáveis formando um documento de segurança (1-1), e utilização de um método
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/07 (2010.01), A61K 35/12 (2015.01), A61L 27

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2674 DE 05-04-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.